Table 2.
Effects of IL-19 on resident vascular cells.
| Tissue type | Effect | Species | Source |
|---|---|---|---|
| EC | Autoinduces IL-19 expression | h | [40] |
| Activates STAT3, Rac1, and MAPK p44/42 | h | [40] | |
| Increases EC proliferation | h | [40] | |
| Increases EC spreading, and migration | h | [40] | |
| Proangiogenic (increase tube, microvessel formation) | m | [40] | |
| Inhibits HuR nucleocytoplasmic translocation | h | [67] | |
|
| |||
| VSMC | Inhibits proliferation, hyperplasia | h, r | [41] |
| Autoinduces IL-19 expression | h | [41] | |
| STAT3 phosphorylation, translocation | h | [41] | |
| Increases SOCS5 expression | h | [41] | |
| Inhibits MAPKs (p44/42, p38) | h | [41] | |
| Decreases inflammatory, proliferative proteins, and mRNAs | h | [68] | |
| Decreases HuR protein abundance | h | [68] | |
| Inhibits HuR nucleocytoplasmic translocation | h | [68] | |
| Decreases ARE-bearing mRNA stability | h | [68] | |
| Inhibits PKCα activation | h | [68] | |
| Inhibits migration, spreading | h | [69] | |
| Inhibits activation of MLC, cofilin, Hsp70, Rac1, and RhoA | h | [69] | |
| STAT3-dependent increase heme oxygenase-1 expression | h | [70] | |
| Decreases ROS in vitro and in vivo | h, m | [70] | |
| Inhibits apoptosis | h | [70] | |
Abbreviations: h: human, m: mouse, r: rat.